Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.14
NAVB's Cash to Debt is ranked lower than
95% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. NAVB: 0.14 )
Ranked among companies with meaningful Cash to Debt only.
NAVB' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.14

Equity to Asset -3.28
NAVB's Equity to Asset is ranked lower than
99% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAVB: -3.28 )
Ranked among companies with meaningful Equity to Asset only.
NAVB' s 10-Year Equity to Asset Range
Min: -3.6   Max: 0.94
Current: -3.28

-3.6
0.94
F-Score: 4
Z-Score: -52.10
M-Score: -1.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -352.12
NAVB's Operating margin (%) is ranked lower than
68% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. NAVB: -352.12 )
Ranked among companies with meaningful Operating margin (%) only.
NAVB' s 10-Year Operating margin (%) Range
Min: -35429.11   Max: 13.25
Current: -352.12

-35429.11
13.25
Net-margin (%) -409.87
NAVB's Net-margin (%) is ranked lower than
71% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. NAVB: -409.87 )
Ranked among companies with meaningful Net-margin (%) only.
NAVB' s 10-Year Net-margin (%) Range
Min: -36907.59   Max: 938.63
Current: -409.87

-36907.59
938.63
ROA (%) -161.71
NAVB's ROA (%) is ranked lower than
91% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. NAVB: -161.71 )
Ranked among companies with meaningful ROA (%) only.
NAVB' s 10-Year ROA (%) Range
Min: -502.64   Max: 26.69
Current: -161.71

-502.64
26.69
ROC (Joel Greenblatt) (%) -1025.81
NAVB's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. NAVB: -1025.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAVB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4904.17   Max: 145.59
Current: -1025.81

-4904.17
145.59
Revenue Growth (3Y)(%) 58.70
NAVB's Revenue Growth (3Y)(%) is ranked higher than
93% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. NAVB: 58.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAVB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 89.8
Current: 58.7

-100
89.8
EBITDA Growth (3Y)(%) -8.00
NAVB's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. NAVB: -8.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAVB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 141
Current: -8

0
141
EPS Growth (3Y)(%) 8.10
NAVB's EPS Growth (3Y)(%) is ranked higher than
65% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. NAVB: 8.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAVB' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 112.7
Current: 8.1

0
112.7
» NAVB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014
Q3 2014
Q4 2014
Q1 2015
» Details

Insider Trades

Latest Guru Trades with NAVB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 25.36
NAVB's P/S is ranked lower than
68% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. NAVB: 25.36 )
Ranked among companies with meaningful P/S only.
NAVB' s 10-Year P/S Range
Min: 1.9   Max: 203
Current: 25.36

1.9
203
Current Ratio 0.62
NAVB's Current Ratio is ranked lower than
92% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. NAVB: 0.62 )
Ranked among companies with meaningful Current Ratio only.
NAVB' s 10-Year Current Ratio Range
Min: 0.62   Max: 17.92
Current: 0.62

0.62
17.92
Quick Ratio 0.58
NAVB's Quick Ratio is ranked lower than
91% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. NAVB: 0.58 )
Ranked among companies with meaningful Quick Ratio only.
NAVB' s 10-Year Quick Ratio Range
Min: 0.48   Max: 17.8
Current: 0.58

0.48
17.8
Days Inventory 263.31
NAVB's Days Inventory is ranked lower than
83% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. NAVB: 263.31 )
Ranked among companies with meaningful Days Inventory only.
NAVB' s 10-Year Days Inventory Range
Min: 70.99   Max: 1386.56
Current: 263.31

70.99
1386.56
Days Sales Outstanding 57.92
NAVB's Days Sales Outstanding is ranked higher than
53% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. NAVB: 57.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAVB' s 10-Year Days Sales Outstanding Range
Min: 9.77   Max: 371.45
Current: 57.92

9.77
371.45

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.00
NAVB's Price/Median PS Value is ranked lower than
80% of the 784 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. NAVB: 3.00 )
Ranked among companies with meaningful Price/Median PS Value only.
NAVB' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 33.33
Current: 3

0.06
33.33
Earnings Yield (Greenblatt) -12.00
NAVB's Earnings Yield (Greenblatt) is ranked lower than
64% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. NAVB: -12.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
NAVB' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.1   Max: 0
Current: -12

-14.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Navidea Biopharmaceuticals Inc was incorporated in Ohio in 1983 and reincorporated in Delaware in 1988. It is a biopharmaceutical company engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent. Its products include Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help evaluate patients with breast cancer and melanoma. Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on macrophages. This flexible and versatile platform acts as an engine for the design of purpose-built molecules offering the potential to be utilized across a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography, intra-operative and/or optical-fluorescence detection in a variety of disease states. NAV4694 is a Fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. NAV5001 is an Iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinson's disease and other movement disorders, with potential use as a diagnostic aid in dementia. NAV1800 is a radiolabeled monoclonal antibody being developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, with a focus on colorectal cancer. It faces competition from medical product and biotechnology companies, as well as from universities and other non-profit research organizations in the field of cancer diagnostics and treatment. As a developer, manufacturer and marketer of medical products, the Company is subject to regulation by, among other governmental entities, FDA and the corresponding state, local and foreign regulatory bodies in jurisdictions in which its products are sold.
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 
comment on NAVB Mar 15 2013 

More From Other Websites
Navidea Biopharmaceuticals to Present at Jefferies Global Healthcare Conference May 26 2015
Navidea Biopharmaceuticals to Present at Jefferies Global Healthcare Conference May 26 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... May 21 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Financials May 20 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 15 2015
10-Q for Navidea Biopharmaceuticals, Inc. May 13 2015
Navidea Biopharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today May 12 2015
Navidea Reports First Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek® Revenue Guidance May 12 2015
Navidea reports 1Q loss May 12 2015
Navidea reports 1Q loss May 12 2015
Navidea Reports First Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek® Revenue Guidance May 12 2015
Q1 2015 Navidea Biopharmaceuticals Inc Earnings Release - Before Market Open May 12 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
Navidea Secures $60 Million Loan with CRG; Funding to Support Lymphoseek® Commercialization and... May 11 2015
Navidea Secures $60 Million Loan with CRG; Funding to Support Lymphoseek® Commercialization and... May 11 2015
10-K for Navidea Biopharmaceuticals, Inc. May 04 2015
Navidea Biopharmaceuticals to Announce First Quarter 2015 Financial Results on May 12, 2015 Apr 30 2015
Navidea Biopharmaceuticals to Announce First Quarter 2015 Financial Results on May 12, 2015 Apr 30 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Apr 27 2015
Navidea Divests NAV5001, a Non-Core, Development-Stage Imaging Agent for Parkinson's Disease Apr 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK